David Preiss

Active 1971–2026

92
Papers
22,809
Citations
58
h-index
89
i10-index

Citations

Citations per year for David Preiss1985: 3 citations1990: 1 citations1991: 2 citations1992: 3 citations1993: 2 citations1994: 1 citations1995: 2 citations1996: 6 citations1997: 7 citations1998: 1 citations1999: 9 citations2000: 8 citations2001: 12 citations2002: 4 citations2003: 4 citations2004: 5 citations2005: 8 citations2006: 7 citations2007: 12 citations2008: 21 citations2009: 40 citations2010: 78 citations2011: 92 citations2012: 130 citations2013: 132 citations2014: 140 citations2015: 152 citations2016: 217 citations2017: 223 citations2018: 233 citations2019: 752 citations2020: 887 citations2021: 887 citations2022: 781 citations2023: 678 citations2024: 1,174 citations2025: 517 citations2026: 51 citations1986–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,226 citing papers, 18.5% of this breakdownUnited Kingdom: 1,218 citing papers, 10.1% of this breakdownChina: 848 citing papers, 7% of this breakdownItaly: 635 citing papers, 5.3% of this breakdownCanada: 615 citing papers, 5.1% of this breakdownGermany: 534 citing papers, 4.4% of this breakdownAustralia: 463 citing papers, 3.8% of this breakdownNetherlands: 407 citing papers, 3.4% of this breakdownFrance: 346 citing papers, 2.9% of this breakdownSpain: 309 citing papers, 2.6% of this breakdownSweden: 306 citing papers, 2.5% of this breakdownJapan: 279 citing papers, 2.3% of this breakdown
0%18.5%Other 32.1%

Fields

  • Medicine78.5%
  • Biochemistry, Genetics and Molecular Biology10.6%
  • Mathematics1.7%
  • Computer Science1.5%
  • Psychology1.3%
  • Immunology and Microbiology1.2%
  • Other5.2%

Topics

  • Diabetes Treatment and Management8.5%
  • Lipoproteins and Cardiovascular Health7.7%
  • Diabetes, Cardiovascular Risks, and Lipoproteins5.1%
  • Liver Disease Diagnosis and Treatment2.5%
  • Metabolism, Diabetes, and Cancer2.5%
  • Pancreatic function and diabetes2.3%
  • Other71.4%

Coauthors

All papers

Open in search
  1. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brendon L. Neuen, Milton Packer, Vlado Perkovic, Marc S. Sabatine, Scott D. Solomon, Muthiah Vaduganathan, Christoph Wanner, David C. Wheeler, Stephen D. Wiviott, Faı̈ez Zannad - The Lancet 2022 cited by 974

  2. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

    Authors: , , , , , , , , - The Lancet Diabetes & Endocrinology 2019 cited by 1,614

  3. Interpretation of the evidence for the efficacy and safety of statin therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2016 cited by 1,844

  4. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kyoichi Mizuno, Kausik K. Ray, Ian Ford - The Lancet 2010 cited by 2,447

  5. GDF15 mediates the effects of metformin on body weight and energy balance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David B. Savage, Bernard B. Allan, Stephen O’Rahilly - Nature 2019 cited by 570

  6. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

    Authors: , , , , , , , , , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2019 cited by 710

  7. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Т. В. Балахонова, Eiichi Sato, Mayuko Amaha, Tsukasa Nakamura, Kostas Kapellas, Lisa Jamieson, Michael R. Skilton, James A. Blumenthal, Alan L. Hinderliter, Andrew Sherwood, Patrick J. Smith, Michiel A. van Agtmael, Peter Reiss, Marit G. A. van Vonderen, Stefan Kiechl, Gerhard Klingenschmid, Matthias Sitzer, Coen D.A. Stehouwer, Heiko Uthoff, Zhi-Yong Zou, Ana Rosa Cunha, Mário Fritsch Neves, Miles D. Witham, Hyun Woong Park, Moo‐Sik Lee, Jang‐Ho Bae, Enrique Bernal, Kristian Wachtell, Sverre E. Kjeldsen, Michael Hecht Olsen, David Preiss, Naveed Sattar, Edith D. Beishuizen, Menno V. Huisman, Mark A. Espeland, Caroline Schmidt, Stefan Agewall, Ercan Ok, Gülay Aşçı, Eric de Groot, Muriël P.C. Grooteman, Peter J. Blankestijn, Michiel L. Bots, Michael Sweeting, Simon G. Thompson, Matthias Lorenz, For the PROG-IMT and the Proof-ATHERO Study Groups - Circulation 2020 cited by 443

  8. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heather Halls, Charlie Harper, C. Hawkins, William G. Herrington, G. A. Hitman, Hallvard Holdaas, Lisa Holland, Alan G. Jardine, J. Wouter Jukema, John J.P. Kastelein, Sharon Kean, Anthony Keech, Adrienne Kirby, John Kjekshus, Genell L. Knatterud, Robert H. Knopp, Wolfgang Köenig, Michael J. Koren, Vera Krane, Martin Landray, John C. LaRosa, Eva Lonn, Peter W. Macfarlane, Stephen MacMahon, Aldo P. Maggioni, Roberto Marchioli, Ian C. Marschner, Borislava Mihaylova, Lemuel A. Moyé, Sabina A. Murphy, Haruo Nakamura, Andrew Neil, Connie B. Newman, Rachel O’Connell, Chris J. Packard, Sarah Parish, Terje Pedersen, Richard Peto, Marc A. Pfeffer, Neil Poulter, David Preiss, Christina Reith, Paul M. Ridker, Michele Robertson, Frank M. Sacks, Naveed Sattar, Roland E. Schmieder, Patrick W. Serruys, Peter Sever, John Shaw, Charles L. Shear, John Simes, Peter Sleight, Enti Spata, Luigi Tavazzi, Jonathan A. Tobert, Gianni Tognoni, Andrew Tonkin, Stella Trompet, George Varigos, Christoph Wanner, Hans Wedel, Harvey D. White, John Wikstrand, Lars Wilhelmsen, Kate Wilson, Robin Young, Salim Yusuf, Faı̈ez Zannad - The Lancet 2019 cited by 791

  9. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Clearfield, Stuart M. Cobbe, Helen M. Colhoun, Björn Dahlöf, Barry R. Davis, James A. de Lemos, John R. Downs, Paul N. Durrington, Bengt Fellström, Ian Ford, Maria Grazia Franzosi, John A. Fuller, Curt D. Furberg, Robert J. Glynn, David Gordon, Antonio M. Gotto, Richard H. Grimm, Ajay Gupta, C. Hawkins, G. A. Hitman, Hallvard Holdaas, Alan G. Jardine, J. Wouter Jukema, John J.P. Kastelein, Sharon Kean, John Kjekshus, Genell L. Knatterud, Robert H. Knopp, Wolfgang Köenig, Michael J. Koren, Vera Krane, Martin Landray, John C. LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter W. Macfarlane, Stephen MacMahon, Aldo P. Maggioni, Roberto Marchioli, Ian C. Marschner, Lemuel A. Moyé, Sabina A. Murphy, Andrew Neil, Enrico Nicolis, Chris J. Packard, Sarah Parish, Terje R. Pedersen, Richard Peto, Marc A. Pfeffer, Neil R Poulter, Sara Pressel, Jeffrey L. Probstfield, Mahboob Rahman, Paul M. Ridker, Michele Robertson, Frank M. Sacks, Naveed Sattar, Roland E. Schmieder, Patrick W. Serruys, Peter Sever, John Shaw, James Shepherd, Lara M. Simpson, Peter Sleight, Luigi Tavazzi, Gianni Tognoni, Andrew Tonkin, Stella Trompet and 28 more - The Lancet 2022 cited by 246

  10. Cardiac Troponin T and Troponin I in the General Population

    Authors: , , , , , , , , , , , , , , - Circulation 2019 cited by 327

  11. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katherine R. Tuttle, Dominik Steubl, Daisy Massey, Martin Landray, Colin Baigent, Richard Haynes, WG Herrington, S Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masanori Abe, Nader G. Abraham, Sarah Acheampong, P Achiri, JA Acosta, A. Q. Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, Movahedian Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, A. Aitken, R AitSadi, Sendogan Aker, S Akimoto, A Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Leslie N. Aldrich, M Alegata, Lee Alexander, S Alfaress, Mohammad Alhadj Ali, Ahmed Issam Ali, Ahmed Issam Ali, Radica Z. Alicic, A Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, Mora Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, Kwame Ansu, A Apostolidi and 1,572 more - The Lancet Diabetes & Endocrinology 2023 cited by 108

  12. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy

    Authors: - JAMA 2011 cited by 1,385

  13. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stella Trompet, Harvey D. White, Salim Yusuf, Jane Armitage, Anthony Keech, John Simes, Rory Collins, Colin Baigent, Elizabeth H Barnes, Jordan Fulcher, William G. Herrington, Adrienne Kirby, Rachel O’Connell, Pierre Amarenco, Hiroyuki Arashi, Philip J. Barter, D. J. Betteridge, Michael A. Blazing, Gerard J Blauw, Jackie Bosch, Louise Bowman, Eugene Braunwald, Richard Bulbulia, Robert Byington, Michael Clearfield, Stuart M. Cobbe, Björn Dahlöf, Barry R. Davis, James A. de Lemos, John R. Downs, Bengt Fellström, Marcus Flather, Ian Ford, Maria Grazia Franzosi, John A. Fuller, Curt D. Furberg, Robert J. Glynn, Uri Goldbourt, David Gordon, Antonio M. Gotto, Richard Grimm, A Gupta, C. Hawkins, Richard Haynes, Hallvard Holdaas, Jemma C. Hopewell, Alan G. Jardine, John J.P. Kastelein, Sharon Kean, Patricia M. Kearney, George D. Kitas, John Kjekshus, Genell L. Knatterud, Robert H. Knopp, Michael J. Koren, Vera Krane, Martin Landray, John C. LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter W. Macfarlane, Stephen MacMahon, Aldo P. Maggioni, Roberto Marchioli, Lemuel A. Moyé, Sabina A. Murphy, Andrew Neil, Enrico Nicolis and 32 more - The Lancet Diabetes & Endocrinology 2024 cited by 137

  14. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

    Authors: , , , , , , , , , , , , , , , , , , - JAMA 2016 cited by 511

  15. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dominik Steubl, Michaela Petrini, Siegfried Seidi, Martin Landray, Colin Baigent, WG Herrington, Sharirose Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masami Abe, Ned Abraham, Sarah Acheampong, P Achiri, JA Acosta, A A Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, Alastair Aitken, R AitSadi, Sendogan Aker, S Akimoto, Akinwande A. Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Luke Aldrich, M Alegata, Lacy M. Alexander, S Alfaress, Mohammad Alhadj Ali, A Ali, A Ali, Radica Z. Alicic, Arta Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, M. Ochoa de Olza Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, K Ansu, A Apostolidi, N. Arai and 1,571 more - The Lancet Diabetes & Endocrinology 2023 cited by 90

  16. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nita G. Forouhi, N. Charlotte Onland‐Moret, Yvonne T. van der Schouw, Renate B. Schnabel, Jaroslav A. Hubáček, Růžena Kubínová, Miglė Bacevičienė, Abdonas Tamošiūnas, Andrzej Pająk, Romanvan Topor-Madry, Urszula Stepaniak, Sofia Malyutina, Damiano Baldassarre, Bengt Sennblad, Elena Tremoli, Ulf dé Fairé, Fabrizio Veglia, Ian Ford, J. Wouter Jukema, Rudi G. J. Westendorp, Gert J. de Borst, Pim A. de Jong, Ale Algra, Wilko Spiering, Anke H. Maitland‐van der Zee, Olaf H. Klungel, Anthonius de Boer, Pieter A. Doevendans, Charles B. Eaton, Jennifer G. Robinson, David Duggan, John Kjekshus, John R. Downs, Antonio M. Gotto, Anthony Keech, Roberto Marchioli, Gianni Tognoni, Peter S. Sever, Neil R Poulter, David D. Waters, Terje R. Pedersen, Pierre Amarenco, Haruo Nakamura, John J.V. McMurray, James Lewsey, Daniel I. Chasman, Paul M. Ridker, Aldo P. Maggioni, Luigi Tavazzi, Kausik K. Ray, Sreenivasa Rao Kondapally Seshasai, JoAnn E. Manson, Jackie F. Price, Peter H. Whincup, Richard Morris, Debbie A. Lawlor, George Davey Smith, Yoav Ben‐Shlomo, Pamela J. Schreiner, Myriam Fornage, David S. Siscovick, Mary Cushman, Meena Kumari, Nick J Wareham, W. M. Monique Verschuren, Susan Redline, Sanjay R. Patel, John C. Whittaker, Anders Hamsten, Joseph A. Delaney and 33 more - The Lancet 2014 cited by 710

  17. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sagar N. Doshi, Moira Dryburgh, Michael Eddleston, Jim Finlayson, Ahmet Fuat, Jacqueline Furnace, JW Kerr Grieve, Greg Guthrie, Sharon Ham, Emma Isaard, Claudine G. Jennings, Richard J. Johnson, Claire Kerr, Sohail Khan, Kailash Krishnan, Susan Long, A. S. Mackintosh, Mary Joan MacLeod, Terry McCormack, Paul McEleny, Monique Morar, Adnan Nadir, David E. Newby, Colin J. Petrie, David Preiss, Stuart H. Ralston, Marc Randall, Helen Routledge, Saad Shakir, Raj Kumar Sharma, Bridget Shepherd, Don Sims, Gordon Snedden, Jasper Trevelyan, Christopher J. Weir, Robin A.P. Weir, Kirsty Wetherall, Robbie S. Wilson, Adam Wilson, Kris Zutis - The Lancet 2022 cited by 157

  18. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes

    Authors: , , , , , , , , , - JAMA Cardiology 2016 cited by 318

  19. Reverse Causality in Cardiovascular Epidemiological Research

    Authors: , - Circulation 2017 cited by 216

  20. Non-alcoholic fatty liver disease

    Authors: , , - BMJ 2014 cited by 327

  21. Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Society of Nephrology 2023 cited by 44

  22. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

    Authors: , , , , , , , - The Lancet 2009 cited by 1,388

  23. Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction

    Authors: , , , , , , , , , , , , , , , , , - Circulation Heart Failure 2016 cited by 352

  24. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

    Authors: , , , , , , , , , , , , , , , , - BMC Nephrology 2016 cited by 209